1000334-19-9

Upstream product

• 81945-13-3 4-bromo-7-hydroxy-2,3-dihydro-1H-inden-1-one 
• 1000334-05-3 (6-amino-7-methoxy-2,3-dihydro-1H-inden-1-ylidene)acetonitrile 
• 1000334-03-1 4-bromo-7-methoxy-6-nitroindan-1-one 
• 1000334-06-4 3-(2-aminoethylidene)-4-methoxyindan-5-amine 
• 1000334-04-2 (4-bromo-7-methoxy-6-nitro-2,3-dihydro-1H-inden-1-ylidene)acetonitrile 
• 1000334-08-6 N-[2-(6-amino-7-methoxy-2,3-dihydro-1H-inden-1-yl)ethyl]acetamide 
• 1000334-07-5 N-(2-(6-amino-7-methoxy-2,3-dihydro-1H-inden-1-ylidene)ethyl)acetamide 
• 90792-61-3 4-bromo-7-hydroxy-6-nitroindan-1-one 
• 50663-21-3 (para-bromophenyl)-2-propenoate 
• 1000334-09-7 N-[2-(6-amino-7-hydroxy-2,3-dihydro-1H-inden-1-yl)ethyl]acetamide hydrochloride 
• 103-80-0 phenylacetyl chloride 

Relevant academic research and scientific papers

Discovery of a Potent and Orally Bioavailable Melatonin Receptor Agonist

To develop potent and orally bioavailable melatonin receptor (MT1 and MT2) agonists, a novel series of 5-6-5 tricyclic derivatives was designed, synthesized, and evaluated. The synthesized indeno[5,4-d][1,3]oxazole, cyclopenta[c]pyrazolo[1,5-a]pyridine, i

TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF

The present invention provides a compound represented by the formula which is useful as an agent for the prophylaxis or treatment of diseases related to the action of melatonin, or a salt thereof and the like.